Scholars Central

Conference abstractPublished 5 May 2014

Breast cancer subtypes overview with emphasis on racial disparities

Authors: Gabriela Oprea-Ilies, Momin T. Siddiqui

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Breast cancer remains a common cancer diagnosed in women. Its treatment is currently determined by expression of predictive and prognostic markers ER, PR and HER2. More than 50% of breast cancer are ER+/PR+/HER2- and have the best prognosis, due to effective targeted hormonal therapies and a more indolent clinical course. The two HER2+ subtypes represent approximately 20% of breast cancer and prior to targeted therapy, had some of the worst prognosis. The TNT (triple negative tumor) defined as ER/PR/HER2 negative, comprise 10-30% of breast cancers. It has recently emerged as a highly aggressive subtype arising in younger women, prevalent among some ethnic groups (African-American (AA) and Hispanics) and with no available effective targeted therapy using unsupervised gene clustering TNTs may be further subcalssified (basal- like, claudin low, p53 mutated BRCA1 associated etc.), mirroring the different histopathologic appearance, with a range of prognoses and responses to treatment. At molecular levels they show differential expression, by race, of basal cytokeratin, stem cells markers, claudins, growth factors and proliferative genes. In AA women these tumors show signs of aggressivity: clinically are larger at presentation and have a poor outcome; at molecular level they show higher proliferation activity and p53 expression. The high prevalence of TNT, with their accompanying poor survival and unique protein expression patterns, among younger women and particularly younger AA women suggests varying differences in gene-environment. This difference between the TNTs in different ethnic groups is of interest in view of their different biologic behaviors, indicating the need for personalized therapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical & Experimental Pathology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Pathology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Gabriela Oprea-Ilies”
  • BylineArticles whose byline prints “Momin T. Siddiqui”